JMP Securities raised the firm’s price target on BioCryst to $16 from $15 and keeps an Outperform rating on the shares following the Q2 results. Orladeyo delivered another impressive quarter, with sales exceeding consensus and our estimate, providing another data point supporting the path to $1B in peak sales, the analyst tells investors in a research note. The firm thinks new 2024 Orladeyo guidance of $420M-$435M is attainable.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Clarifies Recent Report’s Regulatory Significance
- BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
- BCRX Earnings this Week: How Will it Perform?
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst to Report Second Quarter 2024 Financial Results on August 5